Skip to main content

CG Oncology, Inc.

corporate_fare Company Profile

CG Oncology, Inc.

CGON·NASDAQ·Life Sciences·CIK 0001991792

The company is a late-stage clinical biopharmaceutical company that develops and commercializes cretostimogene grenadenorepvec (cretostimogene). Cretostimogene is an investigational oncolytic immunotherapy designed to eliminate cancer cells directly through selective replication and indirectly by activating an anti-tumor immune response. It is being developed as a potential backbone therapy for patients with bladder cancer. Cretostimogene is currently in clinical development for treating high-risk and intermediate-risk non-muscle invasive bladder cancer (NMIBC), which could address up to 150,000 patients. The company is evaluating cretostimogene as a monotherapy in BOND-003 Cohort C, an ongoing Phase 3 clinical trial for high-risk Bacillus Calmette-Guérin (BCG)-unresponsive NMIBC with carcinoma in situ (CIS), with or without Ta/T1 disease. Enrollment for this cohort is complete, and data was reported in September 2025. This trial formed the basis for the Biologics License Application (BLA) submission to the U.S. Food and Drug Administration (FDA) for the initial indication, which began in the fourth quarter of 2025 and is expected to be completed in 2026. Cretostimogene has received both Fast Track and Breakthrough Therapy designations from the FDA for high-risk BCG-unresponsive NMIBC with CIS with or without Ta or T1 papillary tumors. In April 2024, the company also started BOND-003 Cohort P, an exploratory study of cretostimogene monotherapy in high-risk BCG-unresponsive NMIBC with only Ta/T1 disease. Initial data from Cohort P was reported at the 2025 AUA Annual Meeting, with further data reported at the Society of Urologic Oncology (SUO) 26th Annual Meeting in December 2025.

CG Oncology, Inc. (NASDAQ:CGON) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 22 items for CGON at importance 7 or higher on its 1–10 market-impact scale.

Recent high-impact activity:

  • CG Oncology Expands At-The-Market Offering by $300M to a Total of $550M, Signaling Significant Dilution
  • CG Oncology Accelerates Phase 3 Bladder Cancer Trial Data Readout, Reports Strong Clinical Results

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$4.04M
Net Income
-$161M
Diluted EPS
-$2.08
Op. Cash Flow
-$132.35M
Free Cash Flow
-$132.48M
Gross Profit
-$607K
Operating Income
-$190.77M
Cash & Equivalents
$32.49M
Total Debt
$3M
Debt / Equity
0.00×
Net Margin
-39.85×
Shares Outstanding
80.69M sh
Source: 10-K · filed 2026-02-27 · accession 0001193125-26-079498
$79.5 +0.04% today
52-week range · as of 2026-11-18 $37.01 – $93.95
Market cap
$7.1B
Volume
1.7M (1.0× avg)
3-mo avg 1.6M
Live data · 2026-11-22 12:46 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed CGON - Filings & News (Page 2)

CGON
Jan 13, 2026, 4:47 PM EST
Filing Type: 424B5
Importance Score:
8
Price at Filing: $52.16
Real-time Price: $79.50 info
Change: +$27.34 (+52%) info
Market Cap: $7.098B info
CGON
Jan 09, 2026, 8:45 AM EST
Filing Type: 8-K
Importance Score:
9
Price at Filing: $44.50
Real-time Price: $79.50 info
Change: +$35.00 (+79%) info
Market Cap: $7.098B info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets